Literature DB >> 21901331

L-type Cav1.2 calcium channel is involved in 6-hydroxydopamine-induced neurotoxicity in rats.

Rong Wang1, Zegang Ma, Jun Wang, Junxia Xie.   

Abstract

Evidence suggested that L-type calcium channels may play a key role in the pathogenesis of dopaminergic neuron degeneration. In the present study, effects of L-type Cav1.2 calcium channel on 6-hydroxydopamine (6-OHDA)-induced neurotoxicity were investigated. By the semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) studies, we showed that the expression of L-type Cav1.2 calcium channel α1 subunit mRNA increased in the substantia nigra (SN) of 6-OHDA-lesioned rats. Treatment with nifedipine could improve the apomorphine-induced rotation behavior in 6-OHDA-lesioned rats. Using high-performance liquid chromatography electrochemical detection, we also observed that nifedipine partly restored 6-OHDA-induced dopamine depletion in the striatum of rats. These results suggest that the L-type Cav1.2 calcium channel is associated with the development and progression of dopaminergic neuron degeneration.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21901331     DOI： 10.1007/s12640-011-9271-x

Source DB:  PubMed          Journal:  Neurotox Res        ISSN： 1029-8428            Impact factor:   3.911


  30 in total

1.  Neuroprotection in Parkinson's disease: love story or mission impossible?

Authors:  Gurutz J Linazasoro
Journal:  Expert Rev Neurother       Date:  2002-05       Impact factor: 4.618

2.  Iron on the brain.

Authors:  T A Rouault
Journal:  Nat Genet       Date:  2001-08       Impact factor: 38.330

3.  Acupuncture inhibits oxidative stress and rotational behavior in 6-hydroxydopamine lesioned rat.

Authors:  Yong-Peng Yu; Wei-Ping Ju; Zhen-Guang Li; Dao-Zhen Wang; Yuan-Chen Wang; An-Mu Xie
Journal:  Brain Res       Date:  2010-04-24       Impact factor: 3.252

4.  Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures.

Authors:  Julie A Gaasch; Werner J Geldenhuys; Paul R Lockman; David D Allen; Cornelis J Van der Schyf
Journal:  Neurochem Res       Date:  2007-04-03       Impact factor: 3.996

5.  Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines.

Authors:  W Xu; D Lipscombe
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

6.  Effects of isatin on rotational behavior and DA levels in caudate putamen in Parkinsonian rats.

Authors:  Y Zhou; Z Q Zhao; J X Xie
Journal:  Brain Res       Date:  2001-10-26       Impact factor: 3.252

7.  Cav1.3 channel voltage dependence, not Ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons.

Authors:  Ilva Putzier; Paul H M Kullmann; John P Horn; Edwin S Levitan
Journal:  J Neurosci       Date:  2009-12-09       Impact factor: 6.167

8.  Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.

Authors:  Moussa B H Youdim; Galia Stephenson; Dorit Ben Shachar
Journal:  Ann N Y Acad Sci       Date:  2004-03       Impact factor: 5.691

9.  Nifedipine blocks apamin-induced bursting activity in nigral dopamine-containing neurons.

Authors:  P D Shepard; D Stump
Journal:  Brain Res       Date:  1999-01-30       Impact factor: 3.252

10.  Role of voltage-gated L-type Ca2+ channel isoforms for brain function.

Authors:  J Striessnig; A Koschak; M J Sinnegger-Brauns; A Hetzenauer; N K Nguyen; P Busquet; G Pelster; N Singewald
Journal:  Biochem Soc Trans       Date:  2006-11       Impact factor: 5.407
View more
  6 in total

1.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

2.  Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.

Authors:  Qi-Min Wang; Yu-Yu Xu; Shang Liu; Ze-Gang Ma
Journal:  Oncotarget       Date:  2017-07-18

Review 3.  Voltage-Gated Ca2+ Channels in Dopaminergic Substantia Nigra Neurons: Therapeutic Targets for Neuroprotection in Parkinson's Disease?

Authors:  Nadine J Ortner
Journal:  Front Synaptic Neurosci       Date:  2021-02-26

4.  DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient.

Authors:  Liyong Wang; Lizmarie Maldonado; Gary W Beecham; Eden R Martin; Marian L Evatt; James C Ritchie; Jonathan L Haines; Cyrus P Zabetian; Haydeh Payami; Margaret A Pericak-Vance; Jeffery M Vance; William K Scott
Journal:  Neurol Genet       Date:  2016-04-12

Review 5.  Calcium, Bioenergetics, and Parkinson's Disease.

Authors:  Enrico Zampese; D James Surmeier
Journal:  Cells       Date:  2020-09-08       Impact factor: 6.600

Review 6.  Post-Translational Modification of Cav1.2 and its Role in Neurodegenerative Diseases.

Authors:  Yun Li; Hong Yang; Tianhan He; Liang Zhang; Chao Liu
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.